Compare · BON vs DFTX
BON vs DFTX
Side-by-side comparison of Bon Natural Life Limited (BON) and Definium Therapeutics Inc. (DFTX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BON and DFTX operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.92B, about 521.4x BON ($9.4M).
- Over the past year, BON is down 21.3% and DFTX is up 356.1% - DFTX leads by 377.4 points.
- DFTX has hit the wire 7 times in the past 4 weeks while BON has been quiet.
- DFTX has more recent analyst coverage (5 ratings vs 0 for BON).
PerformanceBON-21.28%DFTX+343.87%
2025-07-22+0.00%2026-07-21
- Company
- Bon Natural Life Limited
- Definium Therapeutics Inc.
- Price
- $1.17-2.92%
- $44.02-2.24%
- Market cap
- $9.4M
- $4.92B
- 1M return
- -8.98%
- +19.86%
- 1Y return
- -21.28%
- +356.07%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 0
- 7
- Recent ratings
- 0
- 5
Latest BON
- SEC Form 3 filed by new insider Zhixiang Gao
- SEC Form 3 filed by new insider Chen Jing Veronica
- SEC Form 3 filed by new insider Hu Yongwei
- SEC Form 3 filed by new insider Xue Yingchun
- SEC Form 3 filed by new insider Ma Xin
- SEC Form 3 filed by new insider Wenjuan Chen
- SEC Form 3 filed by new insider Liu Jing
- SEC Form 3 filed by new insider Gao Jianjun
- BON Unveils Strategic Partnership with Tigerbone Group to Launch New Natural Health Initiatives
- SEC Form 6-K filed by Bon Natural Life Limited
Latest DFTX
- A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Definium Therapeutics Announces New Employee Inducement Grants
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Definium Therapeutics Announces New Employee Inducement Grants
- Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Chief Legal Officer Sullivan Mark sold $585,750 worth of shares (13,008 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 320,571 units (SEC Form 4) (withholding tax)
- Chief Medical Officer Karlin Daniel sold $451,876 worth of shares (10,035 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 503,282 units (SEC Form 4) (withholding obligation)
- Chief Financial Officer Roberts Brandi sold $135,675 worth of shares (3,013 units at $45.03) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 209,487 units (SEC Form 4) (withholding obligation)